1)Kanno M, et al:Third epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan from 2006 to 2015. Cancers(Basel) 11:1180, 2019
2)室野重之・他:咽頭—上咽頭癌.MB ENT 157:77-84,2013
3)脇坂尚宏・他:EBV関連バイオマーカーによる上咽頭癌の治療効果・予後判定.耳鼻61:S66-S71,S87-S88,2015
4)Hirai N, et al:Potential interest in circulating miR-BART17-5p as a post-treatment biomarker for prediction of recurrence in Epstein-Barr virus-related nasopharyngeal carcinoma. PLoS One 11:e0163609, 2016
5)Al-Sarraf M, et al:Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998
6)Fuwa N, et al:The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma:a multiinstitutional phase Ⅱ study. Cancer Med 4:1186-1195, 2015
7)Ueno T, et al:Factors affecting outcomes of alternating chemoradiotherapy for nasopharyngeal cancer. Ann Otol Rhinol Laryngol 123:509-516, 2014
8)八尾 亨・他:Tornwaldt病・側頸囊胞.MB ENT 220:27-33,2018